BioSpace News Archive

Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties.

Vyant Bio, Inc., announced that its special meeting of stockholders on September 20, 2023 was convened and then adjourned, without conducting any business, in order to provide stockholders additional time within which to vote on the proposals as described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on August 16, 2023.

Predicine, Inc., a pioneer in the field of liquid biopsy, announced a new study published in The New England Journal of Medicine, demonstrating the clinical utility of its minimal residual disease Liquid Biopsy Assay in support of Genentech’s Phase 1 Clinical Trial of Divarasib.

uMed, the health and research technology company, today announced The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has selected its service to support the global expansion of its wide-scale study exploring the link between loss of smell and brain disease.

KALA BIO, Inc., announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s Amended and Restated 2017 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635.

Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, and Steve Perrin, Ph.D., President and Chief Scientific Officer, will participate in a panel presentation at the upcoming Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2023, at 8:00 a.m. ET.

inTEST Corporation (NYSE American: INTT) today announced that Nick Grant, President & CEO, and Duncan Gilmour, Chief Financial Officer, will present at the annual LD Micro Main Event XVI Conference in Los Angeles, CA, on Tuesday, October 3, 2023.

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Ian Smith to its Board of Directors effective September 19.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, reported the grant of 33,475 restricted stock units of the company’s common stock to 10 newly hired non-executive officers of the company.

Aspect Imaging, LLC, the global leader in disruptive MRI systems for clinically complex neonatal patients announced its Embrace® Point of Care Neonatal MRI System has received an Innovative Technology contract from Vizient, Inc. the nation’s largest provider-driven healthcare performance improvement company.